These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 23316991)

  • 41. Inhaled insulin helps type 2 diabetics.
    Health News; 2004 Jan; 10(1):15. PubMed ID: 15002388
    [No Abstract]   [Full Text] [Related]  

  • 42. [From human insulin to designer insulin. Why insulin analogs?].
    Jungmann E
    Fortschr Med; 1997 Apr; 115(12):40-1. PubMed ID: 9235302
    [No Abstract]   [Full Text] [Related]  

  • 43. Effects of sensor-augmented pump therapy on glycemic variability in well-controlled type 1 diabetes in the STAR 3 study.
    Buse JB; Kudva YC; Battelino T; Davis SN; Shin J; Welsh JB
    Diabetes Technol Ther; 2012 Jul; 14(7):644-7. PubMed ID: 22524549
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Insulin Pumps.
    Pickup JC
    Diabetes Technol Ther; 2019 Feb; 21(S1):S32-S41. PubMed ID: 30785321
    [No Abstract]   [Full Text] [Related]  

  • 45. Factors Associated With Glycemic Control During Free-Living Overnight Closed-Loop Insulin Delivery in Children and Adults With Type 1 Diabetes.
    Tauschmann M; Thabit H; Leelarathna L; Elleri D; Allen JM; Lubina-Solomon A; Stadler M; Walkinshaw E; Iqbal A; Choudhary P; Wilinska ME; Heller SR; Amiel SA; Evans ML; Dunger DB; Hovorka R
    J Diabetes Sci Technol; 2015 Oct; 9(6):1346-7. PubMed ID: 26451010
    [No Abstract]   [Full Text] [Related]  

  • 46. Inferences and implications. Do results from the Diabetes Control and Complications Trial apply in NIDDM?
    Nathan DM
    Diabetes Care; 1995 Feb; 18(2):251-7. PubMed ID: 7729307
    [No Abstract]   [Full Text] [Related]  

  • 47. Glycemic control and cardiovascular disease--should we reassess clinical goals?
    Cefalu WT
    N Engl J Med; 2005 Dec; 353(25):2707-9. PubMed ID: 16371637
    [No Abstract]   [Full Text] [Related]  

  • 48. An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog.
    Raslova K
    Vasc Health Risk Manag; 2010 Jun; 6():399-410. PubMed ID: 20539842
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Insulin-dose-adjusted HbA1c-defined partial remission phase in a paediatric population--when is the honeymoon over?
    Neylon OM; White M; O Connell MA; Cameron FJ
    Diabet Med; 2013 May; 30(5):627-8. PubMed ID: 23215979
    [No Abstract]   [Full Text] [Related]  

  • 50. Evaluation of treatment satisfaction associated with the use of insulin aspart in continuous subcutaneous insulin infusion.
    Wittlin SD; Marcus AO; Weng CS; Howard CP; Schorr AB;
    Diabetes Technol Ther; 2008 Feb; 10(1):1-10. PubMed ID: 18275357
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of glycemic variability in continuous subcutaneous insulin infusion therapy in type 1 diabetes related to anthropometry and complication status.
    Mehdi SK; Hatfield E; Dornhorst A; Oliver NS
    J Diabetes Sci Technol; 2009 Sep; 3(5):1227-8. PubMed ID: 20144442
    [No Abstract]   [Full Text] [Related]  

  • 52. [Inhaled insulin].
    Krankenpfl J; 2005; 43(4-6):107-8. PubMed ID: 16173123
    [No Abstract]   [Full Text] [Related]  

  • 53. The treat-to-target A1C approach to control type 2 diabetes and prevent complications.
    White RD
    Adv Ther; 2007; 24(3):545-59. PubMed ID: 17660163
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Computerization of the Yale insulin infusion protocol and potential insights into causes of hypoglycemia with intravenous insulin.
    Marvin MR; Inzucchi SE; Besterman BJ
    Diabetes Technol Ther; 2013 Mar; 15(3):246-52. PubMed ID: 23289409
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Glycemic control and major depression in patients with type 1 and type 2 diabetes mellitus.
    de Groot M; Jacobson AM; Samson JA; Welch G
    J Psychosom Res; 1999 May; 46(5):425-35. PubMed ID: 10404477
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glycemic control and preventive care measures of indigent diabetes patients within a pharmacist-managed insulin titration program vs standard care.
    Salvo MC; Brooks AM
    Ann Pharmacother; 2012 Jan; 46(1):29-34. PubMed ID: 22202497
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dose Unit Establishment for a New Basal Insulin Using Joint Modeling of Insulin Dose and Glycemic Response.
    Qu Y; Luo J; Garhyan P; Antalis CJ; Chang AM; Jacober SJ
    J Diabetes Sci Technol; 2018 Jan; 12(1):155-162. PubMed ID: 28466661
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Intensified therapy with insulin analogs in type 2 diabetes: normalizing metabolism and maintaining body weight?].
    Jungmann E; Helling T; Jungmann G; Mertens C; Snelting U
    MMW Fortschr Med; 2000 Oct; 142(43):48. PubMed ID: 11098614
    [No Abstract]   [Full Text] [Related]  

  • 59. Comparison of HbA1c in Chinese patients with type 1 or type 2 diabetes randomized to twice daily insulin lispro low mix 25 or twice daily human insulin mix 30/70.
    Li Y; Li Q; Li CJ; Wang CJ; Zheng YM; Issa M; Zhang J
    Chin Med J (Engl); 2009 Nov; 122(21):2540-6. PubMed ID: 19951567
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Insulin therapy in patients with type 2 diabetes].
    Siegmund T; Schumm-Draeger PM
    MMW Fortschr Med; 2008 May; 150(18):32-5; quiz 36. PubMed ID: 18533606
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.